<DOC>
	<DOCNO>NCT01860118</DOCNO>
	<brief_summary>This proposal seek 1 ) determine whether biomarkers associate Parkinson 's disease ( PD ) susceptibility and/or progression exosome-proteomes derive PD patient versus control , 2 ) determine LRRK2 expression and/or phosphorylation significantly lower exosomes individual treat potent LRRK2 kinase inhibitor sunitinib ( multi-kinase inhibitor compound ) , establish assay on-target effect future LRRK2 inhibitor clinical trial .</brief_summary>
	<brief_title>LRRK2 Other Novel Exosome Proteins Parkinson 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<criteria>Parkinson 's disease inclusion criterion : Inclusion criterion base UK Brain Bank criterion clinical diagnosis PD . These require 1 ) presence bradykinesia either rest tremor rigidity ; 2 ) asymmetric onset ; 3 ) progressive motor symptom 4 ) age onset 2199 year . Control inclusion criterion : age 2199 year , lack PD firstdegree blood relative , lack positive response 3 item PD Screening Questionnaire . For subject : include atypical feature indicative ParkinsonPlus disorder ( Progressive Supranuclear Palsy ( PSP ) , Multiple System Atrophy ( MSA ) , Corticobasal Degeneration ( CBD ) ) include cerebellar sign , supranuclear gaze palsy , apraxia cortical sign , prominent autonomic failure , neuroleptic treatment time onset parkinsonism , active treatment neuroleptic time study entry , History repeat stroke stepwise progression parkinsonism , history repeat head injury , history definite encephalitis , prominent gait imbalance early course ( &lt; 5 year ) , dementia , know severe anemia ( hematocrit &lt; 30 ) , history kidney disease and/or current past glomerular filtration rate ( GFR ) &lt; 60 possibly indicative kidney disease , serious comorbidity may interfere participation study .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>